Neuronetics, Inc. (NASDAQ:STIM) EVP William Andrew Macan Sells 12,175 Shares

Neuronetics, Inc. (NASDAQ:STIM) EVP William Andrew Macan sold 12,175 shares of the stock in a transaction dated Wednesday, February 12th. The stock was sold at an average price of $3.83, for a total value of $46,630.25. Following the completion of the sale, the executive vice president now directly owns 388,647 shares of the company’s stock, valued at approximately $1,488,518.01. This represents a 3.04 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

William Andrew Macan also recently made the following trade(s):

• On Monday, February 10th, William Andrew Macan sold 1,970 shares of Neuronetics stock. The stock was sold at an average price of $3.28, for a total value of $6,461.60.

Neuronetics Stock Up 11.8 %

Shares of Neuronetics stock opened at $4.36 on Friday. The stock has a 50-day moving average price of $2.20 and a 200 day moving average price of $1.42. The company has a debt-to-equity ratio of 4.90, a current ratio of 3.16 and a quick ratio of 2.87. Neuronetics, Inc. has a 1 year low of $0.52 and a 1 year high of $5.07.

Institutional Investors Weigh In On Neuronetics

Several hedge funds have recently bought and sold shares of the business. XTX Topco Ltd purchased a new stake in Neuronetics in the 4th quarter worth about $49,000. Geode Capital Management LLC raised its stake in shares of Neuronetics by 2.8% during the 4th quarter. Geode Capital Management LLC now owns 314,076 shares of the company’s stock worth $506,000 after purchasing an additional 8,466 shares in the last quarter. Tradewinds LLC. acquired a new stake in shares of Neuronetics during the 4th quarter valued at about $32,000. JPMorgan Chase & Co. lifted its holdings in shares of Neuronetics by 10,954.1% during the 4th quarter. JPMorgan Chase & Co. now owns 54,939 shares of the company’s stock valued at $88,000 after buying an additional 54,442 shares during the last quarter. Finally, David J Yvars Group lifted its holdings in shares of Neuronetics by 47.1% during the 4th quarter. David J Yvars Group now owns 46,325 shares of the company’s stock valued at $75,000 after buying an additional 14,825 shares during the last quarter. 53.59% of the stock is owned by hedge funds and other institutional investors.

Neuronetics Company Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.